Objective:To evaluate the ability of arterial hemoglobin oxygen saturation measurement via pulse oximetry (SpO 2 ) to serve as a surrogate for PaO 2 in dogs.Design: Two-part study: prospective observational and retrospective components. Setting: University teaching hospital.Animals: Ninety-two dogs breathing room air prospectively enrolled on a convenience basis. Retrospective evaluation of 1,033 paired SpO 2 and PaO 2 measurements from 62 dogs on mechanical ventilation.Interventions: Dogs with concurrent SpO 2 and PaO 2 measured on room air had a data sheet completed with blood gas analysis. SpO 2 , PaO 2 , and FiO 2 values were collected from medical records of dogs on mechanical ventilation. Measurements and Main Results:Predicted PaO 2 was calculated from SpO 2 using the dog oxyhemoglobin dissociation curve. The correlation coefficient between measured and predicted PaO 2 was 0.49 (P < 0.0001) in room air dogs and 0.74 (P < 0.0001) in ventilated dogs. In room air dogs, Bland-Altman analysis between measured minus predicted PaO 2 versus the average showed a mean bias of −6.0 mm Hg (95% limit of agreement, −35 to 23 mm Hg). The correlation coefficient between PaO 2 /FiO 2 and SpO 2 /FiO 2 ratios was 0.76 (P < 0.0001). After combining data sets, receiver operating characteristic curve analysis showed the optimal cutoff value for detecting hypoxemia (PaO 2 < 80 mm Hg) was an SpO 2 of 95%, with sensitivity and specificity of 77.8% and 89.5%, respectively. Using this cutoff, 6.9% of SpO 2 readings failed to detect hypoxemia, whereas 7.2% predicted hypoxemia that was not present. Conclusions:The SpO 2 was not clinically suitable as a surrogate for PaO 2 , though it performed better in mechanically ventilated dogs. As sensitivity for the detection of hypoxemia was poor, pulse oximetry does not appear to be an acceptable screening test. The SpO 2 /FiO 2 ratio may have value for evaluation of anesthetized dogs on supplemental oxygen. Arterial blood gas analysis remains ideal for assessment of oxygenation.
BackgroundRenal infarcts identified without definitive association with any specific disease process.ObjectiveDetermine diseases associated with diagnosis of renal infarcts in cats diagnosed by sonography or necropsy.Animals600 cats underwent abdominal ultrasonography, necropsy, or both at a veterinary medical teaching hospital.MethodsInformation obtained from electronic medical records. Cats classified as having renal infarct present based on results of sonographic evaluation or necropsy. Time‐matched case‐controls selected from cats that underwent the next scheduled diagnostic procedure.Results309 of 600 cats having diagnosis of renal infarct and 291 time‐matched controls. Cats 7–14 years old were 1.6 times (odds ratio, 95% CI: 1.03–2.05, P = .03) more likely to have renal infarct than younger cats but no more likely to have renal infarct than older cats (1.4, 0.89–2.25, P = .14). All P = .14 are statistically significant. Cats with renal infarcts were 4.5 times (odds ratio, 95% CI: 2.63–7.68, P < .001) more likely to have HCM compared to cats without renal infarcts. Cats with renal infarcts were 0.7 times (odds ratio, 95% CI: 0.51–0.99, P = .046) less likely to have diagnosis of neoplasia compared to cats without renal infarcts. Cats with diagnosis of hyperthyroidism did not have significant association with having renal infarct. Cats with renal infarcts were 8 times (odds ratio, 95% CI: 2.55–25.40, P ≤ .001) more likely to have diagnosis of distal aortic thromboembolism than cats without renal infarcts.Conclusions and Clinical ImportanceCats with renal infarcts identified on antemortem examination should be screened for occult cardiomyopathy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.